These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15655266)

  • 21. The impact of age on effects of pre-hospital initiation of high bolus dose of tirofiban before primary angioplasty for ST-elevation myocardial infarction.
    Hermanides RS; van Houwelingen G; Ottervanger JP; de Boer MJ; Dill T; Hamm C; Stella PR; Boersma E; ten Berg JM; van 't Hof AW;
    Cardiovasc Drugs Ther; 2011 Aug; 25(4):323-30. PubMed ID: 21744314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of adjunctive tirofiban therapy on angiographic and clinical outcomes in patients with ST-segment elevated acute myocardial infarction undergoing primary stenting.
    Yeh KH; Chen MC; Chang HW; Yu TH; Chen CJ; Chen YH; Chai HT; Wang CP; Hang CL; Fu M; Wu CJ; Yip HK
    Jpn Heart J; 2004 Jan; 45(1):31-41. PubMed ID: 14973348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
    Galli M; Maggioni AP; Vassanelli C; Tavazzi L
    Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial.
    Valgimigli M; Tebaldi M; Campo G; Gambetti S; Bristot L; Monti M; Parrinello G; Ferrari R;
    JACC Cardiovasc Interv; 2012 Mar; 5(3):268-77. PubMed ID: 22440491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.
    Valgimigli M; Campo G; Percoco G; Bolognese L; Vassanelli C; Colangelo S; de Cesare N; Rodriguez AE; Ferrario M; Moreno R; Piva T; Sheiban I; Pasquetto G; Prati F; Nazzaro MS; Parrinello G; Ferrari R;
    JAMA; 2008 Apr; 299(15):1788-99. PubMed ID: 18375998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom.
    Bakhai A; Flather MD; Collinson JR; Stevens W; Normand C; Alemao E; Itzler R; Ben-Joseph R
    Int J Cardiol; 2003 Oct; 91(2-3):163-72. PubMed ID: 14559126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The thrombolysis in myocardial infarction risk score in unstable angina/non-ST-segment elevation myocardial infarction.
    Sabatine MS; Antman EM
    J Am Coll Cardiol; 2003 Feb; 41(4 Suppl S):89S-95S. PubMed ID: 12644346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis.
    Circulation; 1997 Sep; 96(5):1445-53. PubMed ID: 9315530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS.
    Morrow DA; Antman EM; Snapinn SM; McCabe CH; Theroux P; Braunwald E
    Eur Heart J; 2002 Feb; 23(3):223-9. PubMed ID: 11792137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tirofiban for myocardial infarction.
    Juwana YB; Suryapranata H; Ottervanger JP; van 't Hof AW
    Expert Opin Pharmacother; 2010 Apr; 11(5):861-6. PubMed ID: 20210689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of reperfusion regimens with or without tirofiban in ST-elevation acute myocardial infarction.
    Martínez-Ríos MA; Rosas M; González H; Peña-Duque MA; Martínez-Sánchez C; Gaspar J; García H; Gaxiola E; Delgado L; Carrillo J; Leyva JL; Lupi E;
    Am J Cardiol; 2004 Feb; 93(3):280-7. PubMed ID: 14759375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction.
    Mahoney EM; Jurkovitz CT; Chu H; Becker ER; Culler S; Kosinski AS; Robertson DH; Alexander C; Nag S; Cook JR; Demopoulos LA; DiBattiste PM; Cannon CP; Weintraub WS;
    JAMA; 2002 Oct; 288(15):1851-8. PubMed ID: 12377083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beneficial effects of intracoronary tirofiban bolus administration following upstream intravenous treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the ICT-AMI study.
    Zhu TQ; Zhang Q; Qiu JP; Jin HG; Lu L; Shen J; Zhao LP; Zhang RY; Hu J; Yang ZK; Shen WF
    Int J Cardiol; 2013 May; 165(3):437-43. PubMed ID: 21940058
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of selective infarct-related artery infusion of tirofiban on myocardial reperfusion and bleeding complications in patients with acute myocardial infarction: the SUIT-AMI trial.
    Chen Y; Zhou P; Yan H; Zhao H; Song L; Liu C; Zhao B; Chi Y; Wang S; Wang J
    J Invasive Cardiol; 2013 Aug; 25(8):376-82. PubMed ID: 23913601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of tirofiban plus heparin versus heparin alone on troponin I levels in patients with acute coronary syndromes.
    Januzzi JL; Hahn SS; Chae CU; Giugliano R; Lewandrowski K; Theroux P; Jang IK
    Am J Cardiol; 2000 Oct; 86(7):713-7. PubMed ID: 11018188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome.
    ten Berg JM; van 't Hof AW; Dill T; Heestermans T; van Werkum JW; Mosterd A; van Houwelingen G; Koopmans PC; Stella PR; Boersma E; Hamm C;
    J Am Coll Cardiol; 2010 Jun; 55(22):2446-55. PubMed ID: 20510211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial.
    Ohman EM; Van de Werf F; Antman EM; Califf RM; de Lemos JA; Gibson CM; Oliverio RL; Harrelson L; McCabe C; DiBattiste P; Braunwald E;
    Am Heart J; 2005 Jul; 150(1):79-88. PubMed ID: 16084152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Facilitated percutaneous coronary intervention (PCI) in patients with acute ST-elevation myocardial infarction: comparison of prehospital tirofiban versus fibrinolysis before direct PCI.
    Möckel M; Bocksch W; Strohm S; Kühnle Y; Vollert J; Nibbe L; Dietz R
    Int J Cardiol; 2005 Aug; 103(2):193-200. PubMed ID: 16080980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycoprotein IIb/IIIa inhibitor (tirofiban) in acute ST-segment elevation myocardial infarction.
    Fang CC; Jao YT; Chen Y; Yu CL; Wang SP
    Angiology; 2009; 60(2):192-200. PubMed ID: 18445614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene mutations of platelet glycoproteins and response to tirofiban in acute coronary syndrome.
    Mansur Ade P; Roggerio A; Takada JY; Caribé PM; Avakian SD; Strunz CM
    Sao Paulo Med J; 2016 Jan; 134(3):199-204. PubMed ID: 26786608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.